Share on StockTwits

bluebird bio (NASDAQ:BLUE) posted its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.45) by $0.39, American Banking reports. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.15 million.

A number of analysts have recently weighed in on BLUE shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock, up previously from $44.00. On a related note, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday, June 16th. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock.

In other bluebird bio news, CEO Nick Leschly sold 8,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $33.62, for a total value of $268,960.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

bluebird bio (NASDAQ:BLUE) traded down 2.75% on Tuesday, hitting $33.55. 276,838 shares of the company’s stock traded hands. bluebird bio has a 52 week low of $17.03 and a 52 week high of $41.75. The stock’s 50-day moving average is $35.25 and its 200-day moving average is $26.43. The company’s market cap is $822.3 million.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.